Blueberries Medical Corp. specializes in the cultivation and production of medicinal cannabis in Colombia. While the company has a strong liquidity position with a current ratio of 2.10, it faces significant profitability challenges, evidenced by a gross margin of only 1.2% and negative EBITDA and net margins. Additionally, the low market cap of $7.43M raises concerns about its growth potential despite the expanding cannabis market. Overall, while liquidity is solid, the financial health indicators suggest a need for operational improvements to achieve sustainability.
Loading financial metrics...
Company has $24K in cash but burned $327K last quarter. At this burn rate, only 0.1 quarters of runway remain without additional financing.
Company posted a loss of $-1.6M over the last year, representing 375.4% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.3M over the last year.
Exceptional revenue growth of 55.7% YoY demonstrates strong market demand and competitive positioning.
Gross margin expanded by 13.4 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 98.0pp, demonstrating strong operational leverage.
Both gross margin (+13.4pp) and operating margin (+98.0pp) are expanding simultaneously, indicating the company is scaling profitably.
Fortress balance sheet: cash covers total debt 2.2×, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q3 (September 30, 2025)